science
Moderna mRNA Flu Vaccine Shows Higher Efficacy Than Standard Shot in Phase 3 Trial
Moderna's mRNA flu vaccine reduced illness rates by about 27 percent compared with standard flu shots in a late-stage trial involving more than 40,000 adults ages 50 and older. The results, published in the New England Journal of Medicine, come after the Food and Drug Administration rejected the company's initial application earlier this year. The FDA is expected to decide on approval by Aug. 5.
May 6, 5:00 PM·2m read1 source
Nbc NewsAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Moderna’s mRNA flu vaccine provided greater protection against illness than standard flu shots in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The trial included more than 40,000 adults ages 50 and older who were randomly assigned to receive either the mRNA vaccine or one of four standard flu shots during the 2024–2025 flu season.
About 2 percent of participants in the mRNA group became ill, compared with 2.8 percent in the standard-shot group. The mRNA vaccine performed about 27 percent better overall. Side effects such as fatigue, headache and arm pain were more common in the mRNA group but were described as mild and short-lived.
Similar reactions are often reported after traditional flu shots.
The efficacy of seasonal flu shots varies and has been as low as 20 percent to 30 percent in some years. Messenger RNA technology is viewed as a way to improve protection because it can be updated more quickly to match circulating strains. Traditional flu vaccines take months to manufacture, requiring health officials to select strains up to 12 months before peak season.
This lead time can result in mismatches if new variants emerge. An mRNA approach would allow decisions later in the year and give manufacturers more flexibility to adjust to changes in the virus. The trial was conducted at 301 sites across 11 countries, including the United States.
Older adults are generally at higher risk of severe flu complications than younger people, with the exception of very young children.
